KDR and renal carcinoma: The findings of current study convincingly suggested that selected 1,3,4 oxadiazole derivatives are potent inhibitors of VEGFR 2 compared to EGFR and can be used in the treatment of cancers where selective VEGFR2 inhibitors are required i.e., renal cancer and to mitigate angiogenesis in other cancers.